If abnormal blood pressure is not identified by a patient's pediatric clinician, it may be years before the abnormal blood pressure is detected, leading to end-organ damage.

These findings suggest that aliskiren was as effective as an angiotensin receptor blocker in attenuating this measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.

Exceptions may be made for women remote from term (less than 32 to 34 weeks of gestation) who improve after hospitalization and do not have significant end-organ dysfunction or fetal deterioration.